An American hemp company will participate in a study focusing on commercial cannabidiol (CBD) brands and their products.
Utah-based Green Rock Hemp Holdings today announced that its PURAURA Naturals brand will participate in a new Radicle ACES (Advancing CBD Education and Science) study.
“We’re applying science to understand the effectiveness of CBD products used by tens of millions of Americans every day,” say Radicle Science Co-Founder and CEO Jeff Chen. “We’re partnering with 13 leading CBD brands and collaborators across five top-tier research universities to drive accurate, transparent, and actionable insights for all stakeholders.”
The Largest Study To-Date
The randomized controlled study, which Green Rock says is the largest and most comprehensive of its kind, will utilize a direct-to-consumer approach and collect data on 13 commercial brands and approximately 3,000 participants.
According to Green Rock, participants of the four-week study will use the Radicle Science platform to track the effectiveness of ingested CBD products on well-being, quality of life, pain, sleep, and anxiety.
To gather geographical, ethnic, age, behavioral, and pre-existing health condition outcome data, Green Rock says Radicle ACES will use validated, standardized health indices.
Radicle Science Co-Founder and Executive Chair Pelin Thorogood says that no one else in the CBD market has conducted a rigorous scientific study of the same magnitude before.
“Radicle ACES is driven by our deep commitment to contribute to the body of evidence to support growing demand from consumers and healthcare providers,” says Thorogood. “Given the scale, the diversity of the participant population and the wide range of high-quality commercial brands included, Radicle ACES promised to deliver rich, objective health outcome data for a variety of common health conditions, with the potential to offer unprecedented guidance on CBD effectiveness based on demographic or behavioral differences.”
Green Rock says the real-world data will facilitate scientific understanding regarding dosages, usage patterns, user characteristics, and efficacy, as well as modifiers of treatment response.
The Radicle ACES findings will focus on the two most-prominent barriers to CBD usage, as identified by a 2019 Nielsen study.
The first barrier is the difficulty of determining specific product effectiveness.
The second barrier is the lack of research data on health benefits.
Regarding product efficacy, Green Rock Hemp Holdings CEO Joseph Cachey says the Radicle ACES study is groundbreaking because it will provide concrete scientific data rather than anecdotal evidence.
“Radicle has unparalleled experience leading research on Cannabinoids, so the study will be based on integrity and transparency,” says Cachey. “These are the same principles shared by Enhanced Botanicals—integrity of raw materials, transparency in ingredients and testing, and consistency in developing high-quality products our customers can count on.”
Following the completion of the study, Radicle Aces will release the results in October 2021.